Insights into clinical studies in cardiac surgery from the American Heart Association’s Scientific Sessions 2021: Part two
- VernacularTitle:2021年美国心脏学会心血管外科热点研究解读（二）
- Author:
Jianyu QU
1
;
Heng ZHANG
1
;
Zhe ZHENG
1
Author Information
1. Department of Cardiovascular Surgery, National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, 100037, P. R. China
- Publication Type:Journal Article
- Keywords:
American Heart Association's Scientific Sessions 2021;
randomized controlled trial;
cardiovascular surgery
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2022;29(05):542-546
- CountryChina
- Language:Chinese
-
Abstract:
In the late-breaking trials session of the American Heart Association’s Scientific Sessions 2021, which took place in November 2021, six clinical trials in cardiac surgery published their primary results. This review will look into three of them including the management of patients with moderate or less-than-moderate tricuspid regurgitation at the time of surgery for degenerative mitral regurgitation, timing of ticagrelor cessation before coronary artery bypass grafting, and long-term outcomes of ticagrelor-based antiplatelet therapy for secondary prevention of coronary artery bypass grafting.
